News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Klifovet’s client base comprises the world’s top animal health and nutrition companies as well as many promising startups
In his previous assignment Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
Subscribe To Our Newsletter & Stay Updated
